Unsuccessful treatment with cidofovir and cytarabine in progressive multifocal leukoencephalopathy associated with dermatomyositis N Tubridy MRCP C Wells MRPharmS 1 D Lewis FRCP 1 F Schon FRCP J R Soc Med 2000;93:374±375 Treatment options for progressive multifocal leukoencephalopathy (PML) are very limitedÐparticularly since, in a large trial, cytarabine showed no bene®t in PML associated with human immunode®ciency virus (HIV) 1 . In PML associated with HIV, highly active antiretroviral treatment does prolong survival 2 . Favourable outcomes with cidofovir 3±5 have been reported in three patients, all with coexistent HIV disease.
CASE HISTORY
A woman aged 43 was referred with a 4-week history of gradually progressive gait ataxia and slurred speech. 5 years previously a purple rash had developed around her eyes with coincident changes in the skin on the knuckles of both hands. Dermatomyositis had been diagnosed on the basis of the clinical ®ndings, positive anti-Jo1 antibodies and a muscle biopsy. She was initially treated with prednisolone but after a year azathioprine (3 mg/kg daily) was added and continued for 3 years. She had received no azathioprine for eighteen months before her current presentation, when she was taking only prednisolone 10 mg daily. She was negative for HIV antibody and plasma RNA, and results of cerebrospinal¯uid examination, including polymerase chain reaction (PCR) for JC and BK viruses, were completely normal. Magnetic resonance imaging (MRI) showed high signal in the cerebellum on T2-weighted images which progressed rapidly over two weeks (Figure 1 ). The lesions did not enhance with gadolinium. MR spectroscopy revealed a loss of N-acetyl aspartate in keeping with axonal damage. Cerebellar biopsy con®rmed the diagnosis of PML, showing typical intranuclear inclusion bodies which were positive with an antibody against JC virus.
Her steroid regimen was rapidly tailed off. She was treated with fortnightly pulses of intravenous cidofovir (5 mg/kg), after hydration and probenecid, and with fortnightly cytarabine (5 mg/kg) over ®ve days for three weeks. However, she continued to deteriorate rapidly, with new brainstem and corticospinal tract involvement, and died within three months of the onset of her illness.
COMMENT PML has been well described after renal and bone marrow transplantation but there are no previous reports of its association with dermatomyositis. This case highlights the need for vigilance with the increasing use of immunosuppressive regimens in autoimmune diseases. The negative PCR for JC virus is also notable in view of the alleged high sensitivity of this technique and is a reminder of the need for brain biopsy when PCR is negative. Cidofovir was approved in 1998 for the treatment of cytomegalovirus retinitis in patients with AIDS: it is active in vivo against a wide variety of DNA viruses including JC virus. The current case illustrates the appalling prognosis for most patients with PML and cautions against early optimism, based on a small number of case reports, regarding cidofovir. In a patient with apparent primary hyperparathyroidism, the possibility of familial hypocalciuric hypercalcaemia must be considered.
A woman was referred in 1994, at the age of 40, for control of her hypertension. Her medical history included migraine, pregnancy-induced hypertension, angina and insulin-dependent diabetes mellitus. She was obese with a blood pressure of 220/110 mmHg; the abnormal laboratory ®ndings were a total serum cholesterol of 8.9 mmol/L and serum calcium 2.89 mmol/L (normal range 2.20±2.64) with intact parathyroid hormone (PTH) 33 ng/L (5±55). She was treated with four different antihypertensive agents but her blood pressure was not controlled; there were doubts about her compliance with the medication. Her diabetes control was also poor, re¯ecting a combination of insulin resistance and dietary indiscretion. Between 1995 and 1998 she was admitted several times for chest pain, uncontrolled hypertension and infections related to poor diabetic control. During these admissions her serum calcium was persistently high (2.63±3.18 mmol/L) and in 1998 the hypercalcaemia was investigated in detail. Her medications included bendro¯uazide, which was then stopped; however, her serum calcium remained raised at 2.95 mmol/L with PTH 53 ng/L. She was not receiving any calcium or vitamin D supplements. Further tests were all normal including serum angiotensin converting enzyme and uric acid concentrations, thyroid function tests and urine catecholamine excretion. Urinary calcium excretion (Ca E ), measured in the fasting state and related to glomerular ®ltration rate 1 (GF), was 0.037 mmol/L GF (0.010±0.045) and this, together with borderline low tubular maximum reabsorption of phosphate (TmP/GFR 0.69 mmol/L, reference range 0.71±1.36) and persistence of non-suppressed PTH, suggested a diagnosis of primary
